-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CpLWu9ARx2e3UmuP0NtL8M8BGpV6lq6PhG66kH9YF9lDTuYehtcH75gP7Ke4yjSE +8+RHywzOqRbVmyWezpCFQ== 0000950135-97-000745.txt : 19970222 0000950135-97-000745.hdr.sgml : 19970222 ACCESSION NUMBER: 0000950135-97-000745 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19970214 SROS: NONE GROUP MEMBERS: BIOTECHNOLOGY INVESTMENT GROUP L L C ET AL GROUP MEMBERS: COLLINSON HOWE VENTURE PARTNERS, INC. GROUP MEMBERS: EDWARD BLECH TRUST GROUP MEMBERS: JEFFREY J. COLLINSON GROUP MEMBERS: SCHRODER VENTURES LIMITED PARTNERSHIP GROUP MEMBERS: SCHRODER VENTURES U.S. TRUST GROUP MEMBERS: SCHRODERS INCORPORATED SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CELL THERAPEUTICS INC CENTRAL INDEX KEY: 0000891293 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911533912 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-48459 FILM NUMBER: 97536370 BUSINESS ADDRESS: STREET 1: 201 ELLIOTT AVE W STREET 2: STE 400 CITY: SEATTLE STATE: WA ZIP: 98119 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BIOTECHNOLOGY INVESTMENT GROUP L L C ET AL CENTRAL INDEX KEY: 0000937793 STANDARD INDUSTRIAL CLASSIFICATION: [] IRS NUMBER: 061415704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 1055 WASHINGTON BOULEVARD STREET 2: C/O COLLINSON HOWE VENTURE PARTNERS INC CITY: STAMFORD STATE: CT ZIP: 06901 BUSINESS PHONE: 2033247700 MAIL ADDRESS: STREET 1: 1055 WASHINGTON BLVD STREET 2: C/O COLLINSON HOWE VENTURE PARTNERS INC CITY: STAMFORD STATE: CT ZIP: 06901 SC 13G 1 CELL THERAPEUTICS 1 ----------------------------- OMB APPROVAL ----------------------------- OMB Number: 3235-0145 Expires: December 31, 1997 Estimated average burden hours per response . . .14.90 ----------------------------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. )* Cell Therapeutics, Inc. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, no par value - -------------------------------------------------------------------------------- (Title of Class of Securities) N/A ---------------------------- (CUSIP Number) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 2 - ------------------------- --------------------------------- CUSIP NO. N/A 13G PAGE 2 of 17 PAGES --------- -- ---- - ------------------------- --------------------------------- - -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON BIOTECHNOLOGY INVESTMENT GROUP, LLC ("BIO") N/A - -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] - -------------------------------------------------------------------------------- 3. SEC USE ONLY - -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware - -------------------------------------------------------------------------------- 5. SOLE VOTING POWER NUMBER -0- OF SHARES -------------------------------------------------------- BENEFICIALLY 6. SHARED VOTING POWER OWNED BY EACH 3,313,433 REPORTING -------------------------------------------------------- PERSON 7. SOLE DISPOSITIVE POWER WITH -0- -------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 3,313,433 - -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,313,433 - -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* [ ] - -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 18.8% - -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON* 00 - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! 3 - ------------------------- -------------------------------- CUSIP NO. N/A 13G PAGE 3 of 17 PAGES ---------- --- ---- - ------------------------- ------------------------------- - ------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON EDWARD BLECH TRUST ("EBT") N/A - ------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] - ------------------------------------------------------------------------------ 3. SEC USE ONLY - ------------------------------------------------------------------------------ 4. CITIZENSHIP OR PLACE OF ORGANIZATION New York - ------------------------------------------------------------------------------ 5. SOLE VOTING POWER -0- NUMBER OF ----------------------------------------------------- SHARES 6. SHARED VOTING POWER BENEFICIALLY OWNED BY 3,313,433 EACH ----------------------------------------------------- REPORTING 7. SOLE DISPOSITIVE POWER PERSON WITH -0- ----------------------------------------------------- 8. SHARED DISPOSITIVE POWER 3,313,433 - ------------------------------------------------------------------------------ 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,313,433 - ------------------------------------------------------------------------------ 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* [ ] - ------------------------------------------------------------------------------ 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 18.8% - ------------------------------------------------------------------------------ 12. TYPE OF REPORTING PERSON* 00 - ------------------------------------------------------------------------------ *SEE INSTRUCTIONS BEFORE FILLING OUT! 4 - -------------------------- ----------------------------------- CUSIP NO. N/A 13G PAGE 4 of 17 PAGES ---------- --- ---- - -------------------------- ----------------------------------- - -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON COLLINSON HOWE VENTURE PARTNERS, INC. N/A - -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] - -------------------------------------------------------------------------------- 3. SEC USE ONLY - -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware - -------------------------------------------------------------------------------- 5. SOLE VOTING POWER -0- NUMBER OF ------------------------------------------------------- SHARES 6. SHARED VOTING POWER BENEFICIALLY OWNED BY 3,313,433 EACH ------------------------------------------------------- REPORTING 7. SOLE DISPOSITIVE POWER PERSON WITH -0- ------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 3,313,433 - -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,313,433 - -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* [ ] - -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 18.8% - -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON* CO - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! 5 - ---------------------------- --------------------------- CUSIP NO. N/A 13G PAGE 5 of 17 PAGES ---------- --- ---- - -------------------------- --------------------------- - -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON SCHRODERS INCORPORATED ("SI") N/A - -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] - -------------------------------------------------------------------------------- 3. SEC USE ONLY - -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware - -------------------------------------------------------------------------------- 5. SOLE VOTING POWER -0- NUMBER OF ------------------------------------------------------- SHARES 6. SHARED VOTING POWER BENEFICIALLY OWNED BY 3,313,433 EACH ------------------------------------------------------- REPORTING 7. SOLE DISPOSITIVE POWER PERSON WITH -0- ------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 3,313,433 - -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,313,433 - -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* [ ] - -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 18.8% - -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON* CO - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! 6 - -------------------------- -------------------------- CUSIP NO. N/A 13G PAGE 6 of 17 PAGES ---------- --- ---- - -------------------------- -------------------------- - -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON JEFFREY J. COLLINSON ("JJC") N/A 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] - -------------------------------------------------------------------------------- 3. SEC USE ONLY - -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION U.S.A. - -------------------------------------------------------------------------------- 5. SOLE VOTING POWER -0- NUMBER OF ------------------------------------------------------- SHARES 6. SHARED VOTING POWER BENEFICIALLY OWNED BY 3,313,433 EACH ------------------------------------------------------- REPORTING 7. SOLE DISPOSITIVE POWER PERSON WITH -0- ------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 3,313,433 - -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,313,433 - -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* [ ] - -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 18.8% - -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON* IN - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! 7 - -------------------------- --------------------------- CUSIP NO. N/A 13G PAGE 7 of 17 PAGES ---------- --- ---- - -------------------------- --------------------------- - -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON SCHRODER VENTURES U.S. TRUST ("SVUST") N/A - -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] - -------------------------------------------------------------------------------- 3. SEC USE ONLY - -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Bermuda - -------------------------------------------------------------------------------- 5. SOLE VOTING POWER -0- NUMBER OF ------------------------------------------------------- SHARES 6. SHARED VOTING POWER BENEFICIALLY OWNED BY 3,313,433 EACH ------------------------------------------------------- REPORTING 7. SOLE DISPOSITIVE POWER PERSON WITH -0- ------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 3,313,433 - -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,313,433 - ------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* [ ] - -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 18.8% - ------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON* 00 - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! 8 - -------------------------- ------------------------------- CUSIP NO. N/A 13G PAGE 8 of 17 PAGES --------- --- ---- - -------------------------- ------------------------------- - -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON SCHRODER VENTURES LIMITED PARTNERSHIP ("SVLP") N/A - -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] - -------------------------------------------------------------------------------- 3. SEC USE ONLY - -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware - -------------------------------------------------------------------------------- 5. SOLE VOTING POWER -0- NUMBER OF ------------------------------------------------------- SHARES 6. SHARED VOTING POWER BENEFICIALLY OWNED BY 3,313,433 EACH ------------------------------------------------------- REPORTING 7. SOLE DISPOSITIVE POWER PERSON WITH -0- ------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 3,313,433 - -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,313,433 - -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* [ ] - -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 18.8% - -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON* PN - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! 9 - ------------------------- ------------------------------------ CUSIP NO. N/A 13G PAGE 9 OF 17 PAGES --------- --- ---- - ------------------------- ------------------------------------ Item 1(a). Name of Issuer: --------------- Cell Therapeutics, Inc. Item 1(b). Address of Issuer's Principal Executive Offices: ------------------------------------------------ 201 Elliott Avenue West, Suite 400 Seattle, WA 98119 Item 2. Names, Addresses and Citizenship of Persons Filing: --------------------------------------------------- I. For Reporting Person -------------------- BIOTECHNOLOGY INVESTMENT GROUP, L.L.C.: a) Biotechnology Investment Group, L.L.C. ("BIO") b) c/o Collinson Howe Venture Partners, Inc. 1055 Washington Boulevard Stamford, CT 06901 c) Place of Organization -- Delaware II. REGARDING REPORTING PERSON EDWARD BLECH TRUST: a) Edward Blech Trust b) 418 Avenue I Brooklyn, NY 11231 c) Trusted created under laws of New York REGARDING REPORTING PERSON COLLINSON HOWE VENTURE PARTNERS, INC. a) Collinson Howe Venture Partners, Inc. b) 1055 Washington Boulevard Stamford, CT 06901 c) Place of Organization - Delaware REGARDING REPORTING PERSON SCHRODERS INCORPORATED: a) Schroders Incorporated ("SI") b) 787 Seventh Avenue, 29th Floor New York, NY 10019 c) Place of Organization -- Delaware 10 - -------------------- -------------------------- CUSIP NO. N/A 13G PAGE 10 of 17 PAGES -------- ---- ---- - -------------------- -------------------------- REGARDING REPORTING PERSON JEFFREY J. COLLINSON: a) Jeffrey J. Collinson b) 1055 Washington Boulevard, Stamford, CT 06901 c) Citizenship - United States REGARDING REPORTING PERSON SCHRODER VENTURES US TRUST: a) Schroder Ventures U.S. Trust ("SVUST") b) c/o Schroder Venture Managers Limited 22 Church Street Hamilton HM 11, Bermuda c) SVUST is a closed-end unit trust created under the laws of Bermuda REGARDING REPORTING PERSON SCHRODER VENTURES LIMITED PARTNERSHIP: a) Schroder Ventures Limited Partnership ("SVLP") b) c/o Schroder Ventures Management L.P. 787 Seventh Avenue 29th Floor New York, NY 10019 c) Place of organization -- Delaware ITEM 2(d). Title of Class of Securities: ----------------------------- Common Stock ITEM 2(e). Cusip Number: ------------- N/A ITEM 3. If this statement if filed pursuant to Rules 13D-1(b), Or 13D-2(b), ------------------------------------------------------------------- Check whether the person filing is a: ------------------------------------ (a) [ ] Broker or Dealer registered under Section 15 of the Securities Exchange Act of 1934 (the "Act"), (b) [ ] Bank as defined in Section 3(a)(6) of the Act, (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act, (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940, (e) [ ] Investment Advisor registered under Section 203 of the Investment Advisers Act of 1940, (f) [ ] Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see Rule 13d-1(b)(1)(ii)(f) of the Act, (g) [ ] Parent Holding Company, in accordance with Rule 13d-1(b)(ii)(G) of the Act; see Item 7, 11 - --------------------- ------------------------- CUSIP NO. N/A 13G PAGE 11 of 17 PAGES ---------- ---- ---- - --------------------- ------------------------- (h) [ ] Group, in accordance with Rule 13d-1(b)(1) (ii)(H) of the Act. Not Applicable. ITEM 4. Ownership: ---------- See Items 5-8 on cover pages. ITEM 5. Ownership of Five Percent or Less of a Class: --------------------------------------------- Not Applicable. ITEM 6. Ownership of More than Five Percent on Behalf of Another -------------------------------------------------------- Person: ------- Not Applicable. ITEM 7. Identification and Classification of The Subsidiary which --------------------------------------------------------- Acquired the Security Being Reported on By the Parent ----------------------------------------------------- Holding Company: ---------------- Not Applicable. ITEM 8. Identification and Classification of Members of the Group: ---------------------------------------------------------- Not applicable. ITEM 9. Notice of Dissolution of Group: ------------------------------- Not Applicable. ITEM 10. Certification: -------------- Not Applicable. This statement on Schedule 13G is not filed pursuant to Rule 13d-1(b). 12 - -------------------- ------------------------ CUSIP NO. N/A 13G PAGE 12 of 17 PAGES ---------- ---- ---- - -------------------- ------------------------ SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 14, 1997 BIOTECHNOLOGY INVESTMENT GROUP, L.L.C. ----------------- Date By: COLLINSON HOWE VENTURE PARTNERS, INC. Its: Managing Member By: * -------------------------------------- Jeffrey J. Collinson, President EDWARD BLECH TRUST By: * --------------------------------------- Mordechai Jofen, as Sole Trustee COLLINSON HOWE VENTURE PARTNERS, INC. By: * --------------------------------------- Jeffrey J. Collinson, President * ------------------------------------------ Jeffrey J. Collinson SCHRODERS INCORPORATED By: * --------------------------------------- Jeffrey J. Collinson, Its Attorney-in-Fact SCHRODER VENTURES U.S. TRUST By: SCHRODER VENTURE MANAGERS LIMITED Its: Manager By: * --------------------------------------- Peter Everson 13 - --------------------- -------------------------- CUSIP NO. N/A 13G PAGE 13 of 17 PAGES ---------- ---- ---- - --------------------- -------------------------- SCHRODER VENTURES LIMITED PARTNERSHIP By: SCHRODER VENTURES MANAGEMENT L.P. Its: General Partner By: SCHRODER VENTURE MANAGERS INC. Its: General Partner By: * ------------------------------------------ Peter Everson * By: /s/Timothy C. Maguire --------------------------------------- Timothy C. Maguire, Attorney-in-Fact 14 - ---------------------- ----------------------- CUSIP NO. N/A 13G PAGE 14 of 17 PAGES ----------- ---- ---- - ---------------------- ----------------------- EXHIBIT 1 --------- AGREEMENT --------- Pursuant to Rule 13d-1(f)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed on behalf of all of the undersigned with respect to the ownership of shares of Common Stock of Cell Therapeutics, Inc. by any of the undersigned. This agreement may be executed in any number of counterparts, each of which shall be deemed an original. EXECUTED as a sealed instrument this 14th day of February, 1997. BIOTECHNOLOGY INVESTMENT GROUP, L.L.C. By: COLLINSON HOWE VENTURE PARTNERS, INC. Its: Managing Member By: /s/Jeffrey J. Collinson ------------------------------------- Jeffrey J. Collinson, President EDWARD BLECH TRUST By: /s/Mordechai Jofen ------------------------------------- Mordechai Jofen, as Sole Trustee COLLINSON HOWE VENTURE PARTNERS, INC. By: /s/Jeffrey J. Collinson ------------------------------------- Jeffrey J. Collinson, President /s/Jeffrey J. Collinson -------------------------------------- Jeffrey J. Collinson SCHRODERS INCORPORATED By: /s/Jeffrey J. Collinson ------------------------------------- Jeffrey J. Collinson Its: Attorney-in-Fact SCHRODER VENTURES U.S. TRUST By: SCHRODER VENTURE MANAGERS LIMITED Its: Manager By: /s/Peter Everson ------------------------------------- Peter Everson 15 - -------------------- ------------------------- CUSIP NO. N/A 13G PAGE 15 of 17 PAGES --------- ---- ---- - -------------------- ------------------------- SCHRODER VENTURES LIMITED PARTNERSHIP By: SCHRODER VENTURES MANAGEMENT L.P. Its: General Partner By: SCHRODER VENTURE MANAGERS INC. Its: General Partner By:/s/Peter Everson -------------------------------------- Peter Everson 16 - ----------------------- -------------------------- CUSIP NO. N/A 13G PAGE 16 of 17 PAGES ------------ ---- ---- - ----------------------- -------------------------- Exhibit 2 --------- POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below, and each entity for which an authorized signature appears below, hereby constitutes and appoints Timothy C. Maguire and Anne G. Plimpton, and each of them, each with full power to act without the other, his, her or its, as the case may be, true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself, herself or itself, as the case may be, as an individual or in his, her or its, as the case may be, capacity as a general partner of any partnership or a trustee of any trust, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, all in connection with the beneficial ownership of securities held by the undersigned, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the By-laws of the National Association of Securities Dealers, Inc., granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his substitutes, may lawfully do or cause to be done by virtue hereof. This Power of Attorney will remain in effect until revoked by an instrument in writing delivered to the aforesaid attorney(s)-in-fact. The undersigned each acknowledge that Timothy C. Maguire and Anne G. Plimpton are not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934. IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 12th day of February, 1997. BIOTECHNOLOGY INVESTMENT GROUP, L.L.C. By: COLLINSON HOWE VENTURE PARTNERS, INC. Its: Managing Member By: /s/Jeffrey J. Collinson ------------------------------------- Jeffrey J. Collinson, President EDWARD BLECH TRUST By: /s/Mordechai Jofen ------------------------------------- Mordechai Jofen, as Sole Trustee /s/Mordechai Jofen ------------------------------------------ Mordechai Jofen COLLINSON HOWE VENTURE PARTNERS, INC. By: /s/Jeffrey J. Collinson -------------------------------------- Jeffrey J. Collinson, President 17 - ------------------------ ------------------------ CUSIP NO. N/A 13G PAGE 17 of 17 PAGES -------------- ---- ---- - ------------------------ ------------------------ /s/Jeffrey J. Collinson ------------------------------------------ Jeffrey J. Collinson SCHRODERS INCORPORATED By: /s/Jeffrey J. Collinson -------------------------------------- Jeffrey J. Collinson Its: Attorney-in-Fact SCHRODER VENTURES LIMITED PARTNERSHIP By: SCHRODER VENTURES MANAGEMENT L.P. Its: General Partner By: SCHRODER VENTURE MANAGERS INC. Its: General Partner By: /s/Peter Everson ------------------------------------- Peter Everson SCHRODER VENTURES U.S. TRUST By: SCHRODER VENTURE MANAGERS LIMITED Its: Manager By: /s/Peter Everson -------------------------------------- Peter Everson -----END PRIVACY-ENHANCED MESSAGE-----